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hile the United States population under the age
of 65 has tripled since the beginning of the last century,
the number of those over age 65 has increased 11-fold.
At present, 1 in 8 Americans (33.2 million) are over age
65, up from 1 in 25 in 1900 (3.1 million). This trend is
expected to continue. Projections by the US Census
Bureau indicate that the elderly population will more
than double between now and the year 2050, to 80 mil-
lion, when it is estimated that 1 in 5 Americans will be
elderly.
1 The prevalence of dementia rises steeply with
age, doubling every 4 to 5 years from the age of 60, so
that more than one third of individuals over 80 years of
age are likely to have dementia.
2 With increased life
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As life expectancy in the United States continues to increase, the projected numbers of elderly people who will develop
dementia will grow rapidly. This paper reviews four well-established cardiovascular risk factors (type 2 diabetes, hyper-
tension, cholesterol, and inflammation), for which there is longitudinal epidemiological evidence of increased risk
of dementia, Alzheimer’s disease, mild cognitive impairment, and cognitive decline. These risk factors are of special
interest because of their potential modifiability, which may affect the course of cognitive compromise. Diabetes is the
cardiovascular risk factor (CvRF) most consistently associated with cognition. Hypertension in midlife is consistently
associated with cognition, but its associations with late-life hypertension are less clear. Total cholesterol is not con-
sistently associated with cognition. Interleukin-6 and C-reactive protein are inflammatory markers relatively consis-
tently associated with cognition. Composites of the CvRFs increase the risk for dementia in a dose-dependent fashion,
suggesting a cumulative effect of these factors on neuronal stress. In the relatively few studies that have reported
interactions of risk factors, they potentiate each other. The effect of each of these risk factors varies according to
apolipoprotein E genotype. It may be that the effect of these risk factors varies according to the presence of the oth-
ers, and these complex relationships underlie the biological mechanisms of cognitive compromise. This may be crucial
for understanding the effects on cognition of drugs and other approaches, such as lifestyle change, for treating these
risk factors. 
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of elderly people who will develop dementia will grow
rapidly. There are no cures or preventive measures yet
for dementia.
Alzheimer’s disease (AD) remains the most common
cause of dementia in the elderly. The risk factors for AD,
other than age, include female gender, family history, and
at least one apolipoprotein E4 (APOE4) allele.
3 In addi-
tion, cardiovascular risk factors, established as risk fac-
tors for vascular dementia, have also been associated
with AD.
4 These risk factors are of special interest
because of their potential modifiability so they may affect
the course of disease. This paper reviews four well-estab-
lished cardiovascular risk factors (type 2 diabetes, hyper-
tension, cholesterol, and inflammation), for which there
is longitudinal epidemiological evidence of increased risk
of dementia, AD, mild cognitive impairment (MCI), and
cognitive decline. 
No two longitudinal epidemiological studies of demen-
tia have the same methodology, and they each study dis-
tinct populations. Studies differ in when the risk factor is
measured (eg, midlife vs closer to ascertainment of
dementia), in the proportions of people carrying the risk
factor, in the proportion of people being treated for the
risk factor, the methods by which the risk factor was mea-
sured (eg, direct measure, self-report, medical charts), in
the confounders accounted for, and of course, in the out-
come measures (typically AD, vascular dementia, all
cause dementia, MCI, or cognitive decline). For each car-
diovascular risk factor, this paper summarizes its relation-
ships with the cognitive outcomes. For each risk factor we
tabulate the main results of longitudinal epidemiological
studies of dementia, MCI, and cognitive decline, includ-
ing nonsignificant in addition to significant results.
Beyond separate effects of these risk factors, we consider
multiple causes that may underlie the development of
AD and dementia, by discussing combination effects—
involving these risk factors with each other and with
other factors—which particularly affect cognitive com-
promise. 
Type 2 diabetes
Table I presents studies examining risks of dementia,
MCI, and cognitive decline in patients with type 2 dia-
betes and demonstrates, relatively consistently, increased
risks for each of these outcomes. Type 2 diabetes has
been demonstrated to increase risk for dementia in
most,
4-17 but not all,
14,15 prospective epidemiological studies,
with the highest odds ratios approaching 3-fold increased
risk of dementia for diabetic individuals compared with
nondiabetics.
5 Many studies have also shown increased
risk for AD and VaD (eg, ref 30). A recent study suggests
that type 2 diabetes or impaired fasting glucose might be
present in up to 80% of patients with AD.
27A systematic
review of the effect of diabetes on dementia and cogni-
tive decline concludes that these should be considered
consequences and disabling manifestations of diabetes.
28
Recently, even prediabetes (defined as glucose >7.8
mmol/L but <11.0 mmol/L) was associated with demen-
tia (HR 1.77; 95% CI 1.02-3.12) and AD (HR 1.98; 1.12-
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Reference Results (95% CI)
Dementia studies
Schnaider Beeri
5 OR 2.8 (1.4-5.7)
Brayne
6 OR 2.6 (0.9-7.8)
Yaffe
7 OR 2.4 (0.9-6.1)
Ott
8 RR 1.9 (1.3-2.8)
Leibson
9 SMR 1.6 (1.3-2.0)
Whitmer
10 HR 1.5 (1.2-1.8)
Xu
11 HR 1.5 (1.1-2.1)
Peila
12 RR 1.5 (1.0-2.2)
Curb
11,13 RR 1.4 (.97-1.95)
MacKnight
14 RR 1.3 (0.9-1.7)
Hassing
11,15 RR 1.2 (0.8-1.7)
MCI studies
Yaffe
7 OR 1.8 (1.1-2.8)
Luchsinger
16 HR 1.5 (1.0-2.3)
Luchsinger
17 HR 1.4 (1.0-1.9)
Cognitive decline
Gregg
18 OR 1.7 (1.3-2.4)
Logroscino
19 OR 1.3 (1.1-1.6)
Fontbonne
20 OR >2 for 4 of 9 tests
Knopman
21 37% to 165% greater rate of cognitive decline in 
diabetics (depending on the test)
Okereke
22 Diabetics decline faster; global cognition D-.09 
(-.15, -.04)
Hassing
23 Diabetics decline over twice as fast as non 
diabetics
Arvanitakis
24 44% greater rate of cognitive decline in diabetics
Hassing
25 Diabetics decline twice as fast as nondiabetics
Van den Berg
26 Diabetes was not associated with cognitive 
decline
Table I. Risk of dementia, MCI, and cognitive decline in patients with
Type 2 diabetes. OR, odds ratio; RR, relative risk; HR, hazard
ratio; SMR, standard morbidity ratio; D, difference in rates3.50).
27A few epidemiological studies have examined the
longitudinal association between diabetes and MCI,
7,19,20
a state of cognitive compromise preceding AD or frank
dementia, and all showed significantly increased risk for
subjects with diabetes. Impaired fasting glucose, a predi-
abetic condition, was also associated with MCI.
30
Numerous studies have reported consistently increased
risk of cognitive decline in diabetes.
18-26
Diabetes is a complex metabolic disorder that is closely
associated with other risk factors for dementia, such as
age, hypertension, and the metabolic syndrome—a clus-
tering of several commonly occurring disorders (includ-
ing abdominal obesity, hypertriglyceridemia, low high-
density lipoprotein (HDL) level, and hypertension) that
are often associated with diabetes.
31 These risk factors,
together with diabetes-specific characteristics (eg, age
of onset, glycemic control, use of antidiabetes medica-
tions), demographic and socioeconomic factors, and
genetic factors, might be important determinants of the
increased risk of cognitive decline and dementia in indi-
viduals with diabetes.
32,33 Co-occurrence of diabetes and
hypertension greatly increases the risk of dementia
34
and of cognitive decline.
35 High systolic blood pressure
interacted with borderline diabetes
36 and with frank dia-
betes
11 multiplying the risk of AD. Diabetes almost dou-
bled the risk of dementia and AD in the Rotterdam
study, but diabetics taking insulin were at the highest
risk (RR 4.3, 1.7-10.5)
8 suggesting that more severe dia-
betes increases dementia risk. Consistent with these
observations, subjects with longer duration of dia-
betes
18,19,22 or with diabetes complications
34,35 had steeper
cognitive decline. 
The potential mediating effect of APOE4 genotype and
of age in the relationship between diabetes and demen-
tia is less clear. Participants with diabetes and the
APOE4 allele had a risk ratio of 5.5 (CI 2.2-13.7) for AD
compared with those with neither risk factors in the
Honolulu Asia Aging Study,
12 and this was consistent
with neuropathological findings. However, borderline
diabetes was associated with AD only in non-APOE4
carriers in the Kongsholmen study. The effect of age on
the relationships between diabetes and dementia is also
difficult to interpret. The relationship between diabetes
and dementia in the Framingham study was strongest for
participants older than 75
36,54 but diabetes was not associ-
ated with accelerated cognitive decline in 85+ years of
age participants in another study.
26This suggests that fac-
tors other than CVRFs (ie, age, APOE genotype) inter-
act with diabetes to increase the risk of cognitive com-
promise.
Several potential mechanisms underlying the association
between diabetes and dementia have been proposed: 
￿ Diabetes is associated with micro- and/or macrovascu-
lar disease
37 which in turn increase the risk of cognitive
decline and dementia
38,39
￿ Defective insulin receptor signaling pathway (IRSP) in
the central nervous system
40; the IRSP is associated with
vital brain processes including synaptic plasticity,
41-43 neu-
roprotection, neurodegeneration, survival, growth,
energy metabolism, and longevity.
44,45 Insulin receptors
(IR) are abundant throughout the brain,
46 and are
expressed in especially high abundance in regions that
support cognitive function.
47Aβ, the main component
of neuritic plaques, hallmark lesions of AD, decreases
insulin affinity and reduces the binding of insulin to its
receptor
48 preventing rapid activation of specific kinases
required for multiple cellular functions, including long-
term potentiation (LTP).
49 Soluble Aβ oligomers were
recently shown to significantly lower IR responses to
insulin and to cause rapid and substantial loss of neu-
ronal surface IRs.
50The IR desensitization found in AD
brains,
51 hampers the release of A‚ from the intracellu-
lar to the extracellular compartment,
52 which may be a
mechanism for its neurotoxicity.
53
￿ Advanced glycation end products (AGEs) may have a
crucial role in the relationship between diabetes and
dementia.
54-57AGEs, which normally increase with age
and faster with diabetes, are the products of naturally
occurring reactions between reducing sugars, eg, glu-
cose, and free amine-containing proteins or lipids.
54AD
brains have significantly higher levels of AGEs than
normal controls,
58 and in in-vitro studies, AGEs con-
tribute to the formation of amyloid plaques and neu-
rofibrillary tangles.
59,60
Therefore, treatment for diabetes has the potential for
salutary effects on cognitive compromise. In a 24-week
randomized double blind trial, metformin, and its result-
ing improved glycemic control, were associated with
improved memory.
61 Rosiglitazone treatment of Tg2576
mice (transgenic mice overexpressing amyloid precursor
protein) resulted in better spatial learning and memory
abilities and an approximately 25% reduction in Aβ42
levels.
62 Rosiglitazone therapy resulted in improved
memory and selective attention while not affecting glu-
cose levels in a study of 30 AD or MCI nondiabetic sub-
jects during a period of 6 months.
63A trial with 518 mild-
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203-to-moderate AD patients treated with rosiglitazone for
6 months reported significant improvement in cognition
only in patients who did not possess an APOE4 allele.
64
It should be noted that these encouraging results must be
taken with caution in light of recent studies suggesting
increased myocardial infarction and death from cardio-
vascular causes in rosiglitazone users.
65 Craft et al
66-71 have
performed several investigations examining the effect of
intravenous insulin in nondiabetic elderly adults with
AD. Mild-to-moderate AD patients’ immediate and
delayed recall were improved in hyperglycemic and
hyperinsulinemic conditions compared with a saline con-
trol condition. However, normal controls had no change
in their cognition.
71 Intranasal insulin administration has
recently shown some promising effects on memory.
72,73
Substantially reduced neuritic plaques (NPs), the hall-
mark lesions of the AD brain, were found in the brains
of diabetic subjects who during life received a combina-
tion of insulin and another antidiabetic medication.
74 In
a recent search of the literature by the Cochrane control
trial register, however, no appropriate studies were found
for meta-analysis regarding the effect of treatment for
type 2 diabetes and degree of metabolic control on the
development of dementia.
75 Recently, the SALSA study
reported decreased rates of cognitive decline in diabetic
subjects receiving antidiabetic medications (insulin or
oral hypoglycemic) compared with untreated diabetic
subjects (but see refs 8,16). These studies are provocative
and invite systematic investigation of the possible bene-
fits of diabetes medications on cognition, but are not suf-
ficient to draw conclusions. 
Hypertension
The relationships of hypertension with dementia and cog-
nitive decline are less straight forward, as shown in Table
II. Several longitudinal studies suggest that elevated blood
pressure levels or hypertension, both in midlife
10,16,79,81 and
closer to dementia ascertainment,
80,88 are associated with
increased risk of cognitive decline,
21,85,86 MCI,
84 dementia,
10,78-
89 and AD.
34,88 However, some studies do not find these
relationships,
34,89,90 or even find that low blood pressure is
associated with increased risk
80,82 suggesting the possibility
of a U-shaped relationship between blood pressure and
cognition. All the studies reporting negative or opposite
results measured blood pressure closer to dementia ascer-
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Reference Predictor Results (95% CI)
Dementia
Whitmer
10 HTN in midlife HR 1.24 (1.04-1.48) 
Launer
77 BP in midlife OR 4.3 (1.7-10.8) for DBP >95 mm Hg (compared with 80 to 89) and 4.8 (2.0-11.0) for SBP>160 
(compared with 110-139) 
Kivipelto
78 BP in midlife OR 2.8 (1.1-7.2) for SBP>160 mm Hg and 2.3 (1.1-5.1) fo DBP>95
Kivipelto
79 BP in midlife OR 2.3 (1.0-5.5) for SBP>160 mm Hg 
Qiu
80 BP in late life OR 1.6 (1.1-2.2) for SBP>180 mm Hg and OR 1.5 (1.0-2.1) for DBP<65 
Skoog
81 BP at the age of 70 Participants developing dementia at the age of 79-85 had higher SBP and DBP 15 years earlier
Ruitenberg
82 BP in late life RR 0.93 (0.88-0.99) per 10 mm HG SBP and 0.89 (0.79-1.00) per 10 mm HG DBP
Kalmijn
82 BP in midlife RR 1.05 (0.91-1.21) for an increase of 1 SD of DBP and RR 1.07 (0.94-1.22) for SBP
Posner
34 BP in late life BP was not associated with dementia 7 years later
MCI
Kivipelto
84 BP at midlife OR 1.5 (0.8-2.0) for SBP >160 mm Hg
Cognitive decline
Tzourio
85 HTN in late life OR 2.8 (1.6-5.0) for subjects with a drop > 4 points in the MMSE over 4 years
Knopman
21 HTN in late life HTN was associated with greater decline in the digit symbol test but not with delayed recall or letter 
fluency
Mielke
86 BP in late life SBP>160 mm Hg was associated with faster decline in CDR-SOB and MMSE.
Hebert
87 BP in late life BP not associated with a 6-year change in global cognitive function
Posner
34 BP in late life BP not associated with changes in memory, language, or general cognitive function
Table II. Risk of dementia, MCI, and cognitive decline in patients with high blood pressure or a diagnosis of hypertension. OR, odds ratio; RR, rel-
ative risk; HR, hazard ratio; CDR-SOB, clinical dementia rating sum of boxes; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN,
hypertensiontainment, suggesting that: i) hypertension is a risk factor
for dementia several decades later; and ii) high or low
blood pressure are associated with incipient dementia. It
has been suggested that the dementing process per se
might affect blood pressure
91,92 adding a level of complex-
ity to the directionality of the relationship between hyper-
tension and dementia. In addition, the impact of this risk
factor on cognition depends on age. Consistent with the
latter, systolic blood pressure >160 at baseline was associ-
ated with steeper rates of cognitive decline in 85+ individ-
uals (compared with younger hypertensive or oldest old
individuals with lower systolic blood pressure) in the
Cache County study.
86
Another reason for differences among results is the
effect of use of antihypertensive medication. For exam-
ple, in the Honolulu Asia Aging Study, the association
between high blood pressure and AD was strongest
among those who were never treated for hypertension,
77
while in the Kungsholmen Study low diastolic blood
pressure was associated with incident AD and dementia,
particularly in persons who used antihypertensive med-
ication.
80Antihypertensive medication has been shown
to be associated with reduced incidence of AD,
77,93,94 and
with reduced rates of cognitive decline
95 in additional lon-
gitudinal studies. The effect of antihypertensive use on
risk of dementia was particularly pronounced in APOE4
carriers in one study
96 and in men with longer duration of
hypertensive medication use in another.
97 Low diastolic
blood pressure had a synergistic effect with APOE4 to
significantly increase the risk of AD, but antihyperten-
sive medication counteracted the deleterious effect of
high systolic blood pressure in subjects with the APOE4
allele.
98 Six placebo-controlled antihypertensive trials had
dementia or cognitive decline as their secondary out-
comes.
99-104 Reduced risk of incident dementia was found
in one study
102; other studies found reduced cognitive
decline or dementia risk only in post hoc analysis. In a
meta-analysis combining these data, the combined haz-
ard ratio favored treatment (HR 0.87, CI 0.76-1.00). 
Cerebrovascular disease resulting from hypertension is
one major reason for increased risk of dementia and cog-
nitive decline in hypertensive subjects.
105,106Additionally,
direct relationships of hypertension with AD neu-
ropathology have been found. Elevated systolic and dias-
tolic blood pressure in midlife was associated with a
greater number of NPs and neurofibrillary tangles
(NFTs), respectively.
107 Similarly, hypertension was asso-
ciated with increased extent of NPs and NFTs in non-
demented, middle-aged individuals.
108 Hypertension may
cause changes in vessel walls which may lead to hypop-
erfusion,
109 ischemia,
110 or hypoxia of the brain,
111,112 all of
which have been related to the development of AD
pathology.
110-112An association between high blood pres-
sure and hippocampal atrophy was only found in individ-
uals not treated for hypertension,
113 and lower NPs and
NFTs were found in the brains of subjects who were tak-
ing antihypertensive medication
114 and who did not have
cerebrovascular disease, suggesting that hypertension
medication may have an effect on AD neuropathology. 
The studies described in this section suggest that the
interpretation of results of associations of hypertension
with cognition has to be cautious and should take into
consideration antihypertensive medication use, APOE
genotype, subjects’ age, and the presence of other
CVRFs.
Hypercholesterolemia
Similarly to the relationships between hypertension and
cognitive compromise, most of the studies found total
cholesterol measured in midlife to be a significant pre-
dictor of subsequent dementia,
10,79 MCI,
83 or cognitive
decline
84 (Table III). Total cholesterol in midlife was also
associated with AD in some studies
84,123 and especially
with concomitant hypertension. Studies assessing choles-
terol levels later in life have been less consistent in their
ability to show a predictive effect for later cognitive
decline. Several studies did not find a relationship
between cholesterol and dementia
116,117 or even found an
inverse association.
118 Cholesterol was not associated with
AD in several studies.
124-126 The two studies examining
MCI as an outcome did not find an association with cho-
lesterol. 
The question of association between cholesterol and AD
is of particular interest because APOE is the principal
cholesterol carrier protein in the brain,
127 the APOE-4
allele is a marker of both increased risk of AD and
increased plasma cholesterol concentration. Nonetheless,
very few studies report having examined the interactions
of cholesterol, APOE genotype, and AD or dementia
risk. High cholesterol in late life was associated with
higher AD risk in APOE4 noncarriers only,
128 but this
association was found only in APOE4 carriers in another
study.
129 Moderate decrease in cholesterol from midlife
to late life was associated with more impaired cognitive
status, especially in APOE4 carriers.
115
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205Biochemical and cell biology studies suggest that altered
cholesterol metabolism in neurons may underlie patho-
logical processes of AD. Both the generation and clear-
ance of Aβ are regulated by cholesterol. A polymorphism
of CYP46, a gene playing a major role in hydroxylation
of cholesterol and thereby mediating its removal from
the brain, was associated with increased Aβ load in brain
tissue. It was also associated with increased Aβ peptides
and phosphorylated tau protein in cerebrospinal fluid
(CSF).
130 Consistent with this observation, cholesterol was
higher with increasing certainty of AD neuropathologi-
cal diagnosis.
131,132 However, high cholesterol was not asso-
ciated with increased neuritic plaques in the neocortex
or hippocampus,
133 or with Aβ levels in CSF.
134 Since cho-
lesterol increases atherosclerosis which in turn is asso-
ciated with dysregulation of cerebral blood flow and
hypoperfusion, the effects of cholesterol on dementia risk
might not depend only on Aβ mechanisms but also on
vascular mechanisms.
135
Because of some epidemiological studies suggesting an
increased risk of dementia in individuals with elevated
cholesterol, and because of the biological plausibility
underlying this relationship, the protective effect of statins
(3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors), among the most widely prescribed cholesterol-
lowering medications, was postulated.
136 Prospective epi-
demiological studies are inconsistent but not contradictory
in their results, with several finding that statin use is asso-
ciated with decreased risk of AD and dementia
137-138 and
others finding no associations.
140,141A Cochrane review con-
cluded that there is no conclusive evidence to recommend
statins to reduce the risk of AD,
142 but that there is a grow-
ing body of biological and epidemiological evidence sug-
gesting that lowering cholesterol might retard the patho-
genesis of AD. 
Inflammation
Blood elevations of inflammatory markers, specifically C-
reactive protein (CRP) and interleukin-6 (IL-6), have been
shown to be risk factors for dementia (Table IV).
Combination of high levels of several inflammatory mark-
ers in the Conselice Study of Brain Aging
144 was associated
with increasing hazard ratios for dementia, and specifically
high CRP/IL-6 ratios (HR=1.6, 1.03-2.4). As shown in
Table IV, high levels of inflammatory markers are also
consistently associated with greater rates of cognitive
decline. Of interest are the results of the Health, Aging and
Body Composition (ABC) study, in which subjects with
the metabolic syndrome and high levels of inflammatory
markers (IL-6 and CRP) had significantly higher rates of
cognitive decline than subjects with the metabolic syn-
drome but low levels of blood markers of inflammation.
150
The effect of higher IL-6 levels on global and memory
function decline was stronger in APOE4 carriers than in
non-carriers in the Leiden 85+ study,
151 and was associated
with steeper global cognitive decline only in APOE4 car-
riers in the Rotterdam study.
152These observations again
suggest that interpretation of relationships between
inflammation and cognitive compromise have to be cau-
tious and take into consideration of other factors.
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Reference Predictor Results (95% CI)
Kivipelto
79 Midlife OR 1.89 (1.02-3.49) for TC>251 mg/dL
Whitmer
10 Midlife HR 1.42 (1.22-1.66) for TC≥240 mg/dL
Kalmijn
83 Midlife RR 1.10 (0.95-1.26) for an increase of 1SD of TC
Stewart
116 Midlife No associations with baseline TC but increased risk for men with greater declines in TC
Li
117 Late life HR 1.16 (0.81-1.67) for highest 3 TC quartiles compared with lowest
Mielke
118 Late life HR 0.31 (0.11-0.85) for highest TC quartiles compared with lowest
MCI
Kivipelto
22 Midlife OR 1.9 (1.2-3.0) for TC≥6.5 mmol/L 
Reitz
119 Late life TC was not associated with incident MCI
Solfrizzi
28 Late life TC was not associated with incident MCI
Cognitive decline
Solomon
115 Midlife OR 1.8 (1.1-3.0) for midlife to late life TC decrease of more than 0.5 mmol/L
Yaffe
121 Late life OR 1.77 (1.06-2.97) for highest TC quartile compared with lowest
Knopman
21 Late life Hyperlipidemia was not associated with decline in delayed recall, digit symbol, or letter fluency
Reitz
122 Late life TC was not associated with decline in memory, visuospatial, or language abilities
Table III. Risk of dementia, MCI, and cognitive decline in patients with high total cholesterol (TC). OR, odds ratio, RR, relative risk, HR, hazard ratio These longitudinal studies are consistent with the in vitro
and in vivo studies of neurobiological mechanisms asso-
ciated with cognitive function, suggesting a potential role
of inflammation in the development of cognitive compro-
mise. Several lines of evidence support the importance
of inflammation in the pathogenesis of cognitive impair-
ment and AD. Acute-phase proteins, cytokines,
chemokines, and their receptors are upregulated in brains
of AD patients.
153The abundance of activated microglia,
the primary neuronal immune surveillance cell, is a rela-
tively early pathogenic event in patients with AD.
154
Proinflammatory cytokines augment amyloid precursor
protein (APP),
155,156 and in turn, Aβ induces further
release of cytokines.
157 In addition, gene polymorphisms
of several inflammatory mediators have been associated
with increased risk of AD.
158
Based on the epidemiological and biological evidence,
nonsteroidal anti-inflammatory drugs (NSAIDs) are
potential candidate drugs for treatment of AD. However,
except for a clinical trial with indomethacin in which ben-
eficial results were found,
159 trials with NSAIDs show
either nonsignificant beneficial trends
160 or no benefits.
161-
164The failure of these trials might have been for method-
ological reasons (short follow-up period, inadequate time
of intervention, or insufficient dosing). Examination of
anti-inflammation drugs with mechanisms other than
cyclooxygenase inhibition is warranted. 
Conclusions
The relationships of the four reviewed cardiovascular
risk factors with dementia and cognitive decline are com-
plex. Diabetes seems to be the risk factor with the most
consistent associations. Composites of the risk factors
seem to increase in a dose-dependent fashion the risk for
dementia,
2,3,97 suggesting an accumulating effect of these
factors on neuronal stress. In the relatively few studies
that have reported interactions of risk factors, they
potentiate each other rather than simply accumulating
deleterious effects. Moreover, the effect of each of the
risk factors discussed in this review seem to depend on
APOE genotype. If the underlying biological mechanism
CV risk factors and cognitive compromise - Beeri et al Dialogues in Clinical Neuroscience - Vol 11 . No. 2 . 2009
207
Study Predictor Results (95% CI)
Dementia
HAAS
143 CRP OR 2.7 (1.7-4.7) for highest quartile compared with lowest 
Conselice Study of Brain Aging
144 CRP HR 1.63 (1.10-2.39)
ACT HR 1.62 (1.10-2.38)
IL-6 No association
Rotterdam Study
145 CRP RR 1.12 (0.99-1.25)
IL-6 RR 1.28 (1.06-1.55)
ACT RR 1.49 (1.23-1.81)
Cognitive decline
Helsinki Aging Study
146 CRP RR 2.32 (1.01-5.46) for CRP>5 mg/L decline 
Mac Arthur Studies of Successful Aging
147 IL-6 OR 2.03 (1.30-3.19) for upper tertile of IL-6.
Health ABC Study
148 CRP, IL-6 RR 1.66 (1.19-2.32) for high CRP and IL-6, and the metabolic syndrome
TNFα No association
Longitudinal Aging Study Amsterdam
149 ACT Decline in MMSE but not with other cognitive tests
CRP, IL-6 No associations
Leiden 85+ Study
150 IL-6 Decline in memory
CRP, ACT No associations
Rotterdam Study
145 IL-6 Decline in memory in APOE4
CRP, ACT No associations
Edinburgh Artery Study
152 IL-6 Decline in information processing
Fibrinogen Decline in nonverbal reasoning
ICAM-1 Decline in nonverbal reasoning and global cognition
Table IV. Risk of dementia, MCI, and cognitive decline in patients with high inflammatory marker levels. CRP, C-reactive protein; IL-6, Interleukin 6;
TNFα; Tumor necrosis factor α; ACT-alpha-1-antichymotrypsin; ICAM-1-intercellular adhesion molecule-1 *Subjects with metabolic syn-
drome and high CRP or IL-6 had the highest riskdepends on multiple risk factors for its full expression,
the apparent effect of a single risk factor would depend
on whether the others were present. This may be crucial
for understanding the effects on cognition of drugs treat-
ing these risk factors. Thus, these considerations may pro-
foundly affect the results of clinical trials and at least par-
tially explain why epidemiological associations are sel-
dom reflected in clinical trials. Epidemiological indica-
tions of interactions might suggest subgroups to target in
interventional studies.  ❏
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Los efectos de los factores de riesgo 
cardiovascular en el compromiso cognitivo
Dado que la expectativa de vida en los Estados
Unidos continúa incrementándose, el número pro-
yectado de personas de edad avanzada que desarro-
llarán demencia crecerá rápidamente. Este artículo
revisa cuatro factores de riesgo cardiovascular bien
establecidos (diabetes tipo 2, hipertensión, coleste-
rol e inflamación), para los cuales existen evidencias
epidemiológicas longitudinales de un riesgo aumen-
tado de demencia, Enfermedad de Alzheimer, dete-
rioro cognitivo leve y decaimiento cognitivo. Estos
factores de riesgo son de especial interés ya que son
potencialmente modificables, lo que puede influir en
la evolución del compromiso cognitivo. La diabetes
es el factor de riesgo cardiovascular (FRCv) que se
asocia con mayor consistencia con la cognición. La
hipertensión en la edad media de la vida está aso-
ciada consistentemente con la cognición, pero las
asociaciones de esta última con la hipertensión de las
etapas tardías de la vida son menos claras. El coles-
terol total no está asociado consistentemente con la
cognición. La interleukina 6 y la proteína C reactiva
son marcadores inflamatorios con una asociación
relativamente consistente con la cognición. Una com-
binación de los FRCv aumenta el riesgo para demen-
cia de manera dosis-dependiente, lo que sugiere un
efecto acumulativo de estos factores de estrés neu-
ronal. En los relativamente pocos estudios que han
dado cuenta de las interacciones entre los factores
de riesgo, estos se potencian unos con otros. El
efecto de cada uno de los factores de riesgo varía de
acuerdo con el genotipo para la apolipoproteína E.
Puede ser que el efecto de estos factores de riesgo
se modifique según la presencia de los otros, y estas
complejas relaciones estén a la base de los mecanis-
mos biológicos del compromiso cognitivo. Para el tra-
tamiento de los factores de riesgo puede ser crucial
comprender los efectos que tienen en la cognición
los fármacos y otras intervenciones, como el cambio
de estilo de vida. 
Les effets des facteurs de risque 
cardiovasculaire sur le déficit cognitif
L’espérance de vie continuant à augmenter aux
États-Unis, le nombre de sujets âgés qui développe-
ront une démence est appelé à augmenter rapide-
ment. Cet article examine quatre facteurs de risque
cardiovasculaire bien connus (diabète de type 2,
hypertension, cholestérol et inflammation) qui ont
montré lors d’études épidémiologiques longitudi-
nales qu’ils présentaient un risque accru de
démence, de maladie d’Alzheimer, de déficit cogni-
tif léger et de déclin cognitif. Ces facteurs de risque
sont très intéressants car ils peuvent être modifiés,
ce qui pourrait influencer l’évolution du déclin
cognitif. Le diabète est le facteur de risque cardio-
vasculaire (FRCv) le plus régulièrement associé à la
cognition. L’hypertension des sujets d’âge moyen
semble liée aux capacités cognitives, ce qui appa-
raît moins important chez les sujets plus âgés. Le
cholestérol total n’est pas corrélé à la cognition
alors que les marqueurs de l’inflammation interleu-
kine-6 et protéine-réactive C le seraient relative-
ment. Les FRCv augmenteraient le risque de
démence de façon dose-dépendante, avec un
potentiel effet cumulatif sur le stress neuronal.
Dans les relativement rares études qui ont rapporté
des interactions des facteurs de risque, ces derniers
semblaient se potentialiser les uns les autres. Par
ailleurs, l’’effet de chacun d’entre eux varierait
selon le génotype de l’apolipoprotéine E. L’effet de
ces facteurs de risque pourrait varier en fonction de
la présence des autres et ces relations complexes
sous-tendent les mécanismes biologiques du déficit
cognitif. Leur étude apparaît cruciale pour la com-
préhension des effets des médicaments et d’autres
approches thérapeutiques (modification du style de
vie) sur la cognition, afin de traiter ces facteurs de
risque.CV risk factors and cognitive compromise - Beeri et al Dialogues in Clinical Neuroscience - Vol 11 . No. 2 . 2009
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